Emcure Pharmaceuticals Share Price Gains Over 5% After Q2 FY27 Earnings Results: Total Income Up 24% YoY

On November 3, 2026, Emcure Pharmaceuticals Limited reported its unaudited consolidated financial results for the quarter and half year ended September 30, 2026, as per the exchange filings. 

Emcure Pharmaceuticals Q2 FY27 Earnings Results 

Emcure Pharmaceuticals Limited's total income up 24.2% YoY to ₹2,823.73 crore in the September 2026 quarter from ₹2,272.95 crore a year ago, and up 9.3% QoQ from ₹2,582.52 crore in the June 2026 quarter. 

Net profit (PAT) up 29.3% YoY to ₹325.07 crore in the September 2026 quarter from ₹251.37 crore a year ago, and up 11.1% QoQ from ₹292.49 crore in the June 2026 quarter. 

Half-Yearly Financial Results 

For the half year ending September 30, 2026, Emcure Pharmaceuticals reported a total income of ₹5,406.24 crore, reflecting a 23.5% year-on-year increase from ₹4,377.18 crore. The net profit for this period rose by 32.5% year-on-year to ₹617.56 crore, up from ₹466.16 crore in the corresponding period of the previous year. 

Therapeutic and Regional Performance 

The domestic segment generated ₹1,155.30 crore in revenue, driven by the Women's Health portfolio and core clinical franchises. International business grew by 34.5% year-on-year, reaching ₹1,665.20 crore, with European operations contributing ₹604.30 crore, a 36% increase. 

Read More: Marico Share Price Gains Over 7% Post Q2 FY27 Earnings Results: Total Income Up 12.9% YoY! 

Corporate Strategy Updates 

Emcure Pharmaceuticals announced a statutory scheme of amalgamation to merge its subsidiaries, Zuventus Healthcare and Emcutix Biopharmaceuticals, into the parent company. Additionally, MD and CEO Satish Mehta assumed the role of Chairman, consolidating corporate governance. 

Emcure Pharmaceuticals Share Price Performance 

As of November 03, 2026, at 3:03 PM, Emcure Pharmaceuticals share price on NSE was trading at ₹1,988.00, up by 5.55% from the previous closing price. 

Conclusion 

Emcure Pharmaceuticals reported a 24.2% YoY increase in total income to ₹2,823.73 crore for the September 2026 quarter, with net profit rising 29.3% YoY to ₹325.07 crore. Half-yearly income grew 23.5% YoY to ₹5,406.24 crore, while net profit increased 32.5% YoY to ₹617.56 crore. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.